lenalidomide + docetaxel + prednisone

This is a **combination regimen** consisting of lenalidomide, docetaxel, and prednisone, explored primarily for treatment of metastatic castration-resistant prostate cancer (mCRPC). - **Lenalidomide** is an immunomodulatory agent with anti-angiogenic properties, structurally related to thalidomide, that exerts anti-tumor effects via multiple mechanisms, including modulating the immune response and inhibiting tumor vascularization. - **Docetaxel** is a cytotoxic anticancer agent (a taxane) that acts as a microtubule inhibitor, leading to cell cycle arrest and apoptosis in rapidly dividing cells. - **Prednisone** is a synthetic glucocorticoid corticosteroid used to reduce inflammation and as part of a supportive regimen in various cancer chemotherapies. This three-drug combination was investigated in phase 3 studies as first-line therapy for mCRPC, but did **not improve overall survival compared to docetaxel + prednisone** and was associated with increased toxicity, including higher rates of neutropenia, febrile neutropenia, diarrhea, and pulmonary embolism[1][2][4][8]. No unique brand or code name is used for this specific combination.